Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice

Matsuda, Toshihiko; Misato, Kazuki; Tamiya, Shigeyuki; Akeda, Yasuhiro; Nakase, Ikuhiko; Kuroda, Etsushi; Takahama, Shokichi; Nonaka, Motohiro; Yamamoto, Takuya; Yoshioka, Yasuo

doi:10.1016/j.isci.2022.105324

Cited by 2 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein purification. All proteins were generated as previously described (58,59). Detailed methodology is described in Supplemental Methods.…”

Section: Methodsmentioning

confidence: 99%

Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses

Kawai,

Tokunoh,

Kawahara

et al. 2023

Journal of Clinical Investigation

Self Cite

View full text Add to dashboard Cite

Intranasal vaccines are anticipated to be powerful tools for combating many infectious diseases, including SARS-CoV-2, because they induce not only systemic immunity but also mucosal immunity at the site of initial infection. However, they are generally inefficient in inducing an antigen-specific immune response without adjuvants. Here, we developed an adjuvant-free intranasal vaccine platform that utilizes the preexisting immunity induced by previous infection or vaccination to enhance vaccine effectiveness. We made RBD-HA, a fusion of the receptor-binding domain (RBD) of spike derived from SARS-CoV-2 as a vaccine target with HA derived from influenza A virus (IAV) as a carrier protein. Intranasal immunization of previously IAV-infected mice with RBD-HA without an adjuvant elicited robust production of RBD-specific systemic IgG and mucosal IgA by utilizing both HA-specific preexisting IgG and CD4 + T cells. Consequently, the mice were efficiently protected from SARS-CoV-2 infection. Additionally, we demonstrated the high versatility of this intranasal vaccine platform by assessing various vaccine antigens and preexisting immunity associated with a variety of infectious diseases. The results of this study suggest the promising potential of this intranasal vaccine platform to address problems associated with intranasal vaccines.

show abstract

“…Protein purification. All proteins were generated as previously described (58,59). Detailed methodology is described in Supplemental Methods.…”

Section: Methodsmentioning

confidence: 99%

Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses

Kawai,

Tokunoh,

Kawahara

et al. 2023

Journal of Clinical Investigation

Self Cite

View full text Add to dashboard Cite

show abstract

“…The key to further developing subunit vaccines lies in enhancing their immunogenicity ( Slifka and Amanna, 2014 ). Dendritic cells (DC) possess a robust capacity for antigen presentation, it is frequently utilized as targets for antigens which making a major determinant of vaccination ( Cohn et al, 2014 ; Macri et al, 2016 ; Matsuda et al, 2022 ). The recombinant Lactococcus lactis expressing FAdV-4-hexon fusion DC targeting peptide was constructed, which resulted in increased levels of serum IgG and secretory IgA ( sIgA ) in jejunal lavage fluid after oral immunization compared to the PBS and empty vector control groups, providing enhanced protection against FAdV infection ( Jia et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Immunoprotection of FliBc chimeric fiber2 fusion proteins targeting dendritic cells against Fowl adenovirus serotype 4 infection

Li,

Zhou,

et al. 2024

Poultry Science

View full text Add to dashboard Cite

Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice

Cited by 2 publications

References 68 publications

Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses

Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses

Immunoprotection of FliBc chimeric fiber2 fusion proteins targeting dendritic cells against Fowl adenovirus serotype 4 infection

Contact Info

Product

Resources

About